Roche signs $200 million hepatitis C deal
This article was originally published in Scrip
Executive Summary
Rochewill strengthen its hepatitis C portfolio after agreeing to useMetabasis Therapeutics' HepDirect liver-targeting technology for $203 million. Roche will apply the platform to its proprietary lead nucleosides over the next two years to develop new treatments for hepatitis C.